Risk stratification and medical therapy of pulmonary arterial hypertension
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 Time-course of completed randomised controlled trials (RCTs) in pulmonary arterial hypertension (PAH) (n=41) according to treatment strategy. SSc: systemic sclerosis; IPAH: idiopathic PAH. Reproduced and modified from [70] with permission.](https://figures.cochat.ai/paper-figures/44281cb9913845f29b53a42c8e3258e5/risk-stratification-and-medical-therapy-of-pulmonary-arterial-hypertension-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other high-risk profiles include familial PAH, PVOD, CTD-PAH, CTD-PAH associated with concomitant ILD, rapidly progressive disease despite therapy, and development of hemoptysis.(282, 291–293)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, the 2018 World Symposium on Pulmonary Hypertension strongly recommends serial parametric risk assessment.(282)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
The cited source says what the claim attributes to it.
In the citing paper
“The 2018 World Symposium on Pulmonary Hypertension states that the ultimate goal of therapy for patients with PAH is to achieve a low-risk status, assessed either by REVEAL or the ESC/ERS model.(282)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationBenza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Self-citationChannick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,534
Self-citation
Research works printed but not linked: 2
- Benza, 2018, Comparison of three assessment strategies as predictors of one-year survival in US pulmonary arterial hypertension (PAH) patients, Am J Respir Crit Care Med, 197, A7649
- Galiè, 2014, AMBITION: a randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH), Eur Respir J, 44, 2916
Cited by
Items 501–600 of 897
Wang, Y., 林路, Lü, L., Cao, J., Cao, J., Jing, Z., Li, S., Li, S., Wang, X., Jin, Z.-Y., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102492 · Cited by 5
Self-citationNishiura, K., Nakazato, K., Yokokawa, T., Suzuki, Y., Kurosawa, Y., Wada, K., Shimizu, T., Oikawa, M., Kobayashi, A., Sugimoto, K., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196359 · Cited by 5
Wißmüller, M., Wartner, V., Hohmann, C., Adler, J., Kramer, T., Hellmich, M., Gerhardt, F., Baldus, S. E., & Rosenkranz, S. (2023) · European Respiratory Journal · doi:10.1183/13993003.01454-2022 · Cited by 5
Nakayama, K., Nakajima, Y., Tanaka, R., Hirata, K., & Emoto, N. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001447 · Cited by 5
Benza, R. L., Lickert, C. A., Xie, L., Drake, W., Ogbomo, A. S., Yüce, H., & Cole, M. R. (2020) · Pulmonary Circulation · doi:10.1177/2045894020954158 · Cited by 5
Subías, P. E., Pérez, Á. A., Pérez‐Olivares, C., Climent, L. G., Diago, J. I., & Perelló, M. F. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1878027 · Cited by 5
Shoji, M., Matsui, T., Tanaka, H., Nomura, K., Tsujita, H., Kodama, Y., Koba, S., Kobayashi, Y., & Shinke, T. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00332-4 · Cited by 5
BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series
Scelsi, L., Greco, A., Acquaro, M., Olivieri, C., Sobrero, M., Turco, A., Cappelletti, D., Visconti, L. O., & Ghio, S. (2021) · Pulmonary Circulation · doi:10.1177/20458940211037275 · Cited by 5
Demirel, M., Istanbul-Turkey, Kulahcioglu, S., Tokgöz, H. C., Akbal, Ö. Y., Hakgör, A., Karagöz, A., Tanyeri, S., Keskin, B., Kültürsay, B., et al. (2021) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2021.474 · Cited by 5
Xiong, J., Yu, S., Liu, R., Xia, F., & Wu, R. (2021) · Disease Markers · doi:10.1155/2021/2135942 · Cited by 5
Pulmonary Hypertension for the Non-Specialist
Stubbs, H., & Johnson, M. (2021) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2021.419 · Cited by 5
Riociguat in the Treatment of Pulmonary Arterial Hypertension
Jerjes-Sánchez, C., Valdez-López, H. G., Zayas, N., Cueto‐Robledo, G., Bonola, L., Pech-Alonso, B., Ramírez, A., Flores-Puente, F., García‐Aguilar, H., Hernández, G. E., et al. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.04.001 · Cited by 5
Self-citationPulmonary Arterial Hypertension Induces a Distinct Signature of Circulating Metabolites
Rafikov, R., Coletta, D. K., Mandarino, L. J., & Rafikova, O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010217 · Cited by 5
Cardiac Magnetic Resonance Evaluation of Pulmonary Arterial Hypertension
Hulten, E. A., & Bradley, A. J. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.11.022 · Cited by 5
Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension
Uhland, C., Gibbs, A., Insel, M. B., Kubba, S., & Rischard, F. P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042673 · Cited by 4
Wang, J., Jin, J., Zhang, M., Chen, X., Du, S., Mao, X., Bao, C., Zhu, J., Song, X., & Li, S. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04883-5 · Cited by 4
D’Alto, M., Scelsi, L., Giuliani, L., Perna, G. P., Baldi, F., Guerra, F., Poi, E. D., Vicenzi, M., Badagliacca, R., Corda, M., et al. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107585 · Cited by 4
Marqués, R. B., Becerra‐Muñoz, V. M., Espíldora-Hernández, F., & Mayoral, A. R. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.010 · Cited by 4
Tang, H., Lu, F., Huang, Y., Wang, Q., Sun, X., Zhang, M., & Zhou, L. (2024) · Healthcare · doi:10.3390/healthcare12161633 · Cited by 4
The Role of Imaging in Pulmonary Vascular Disease
Jakubowski, B., Griffiths, M., & Goss, K. N. (2024) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2024.07.008 · Cited by 4
Diagnosis and treatment directions and research frontiers of systemic lupus erythematosus
Jiang, N., Bai, W., Zhao, J., Zhang, S., Wu, C., Wang, L., Zhao, L., Li, J., Hu, C., Wang, Q., et al. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0170 · Cited by 4
Ewert, R., Habedank, D., Halank, M., Stubbe, B., & Opitz, C. F. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2011220 · Cited by 4
Chen, Y., Ouyang, T., Yin, Y., Fang, C., Tang, C.-E., Jiang, L., & Luo, F. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1125063 · Cited by 4
Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
Papa, S., Scoccia, G., Serino, G., Adamo, F. I., Jabbour, J. P., Caputo, A., Boromei, M., Filomena, D., Laviola, D., Maggio, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216840 · Cited by 4
Therapeutic potential of organosulfur compounds in pulmonary hypertension
Mirhadi, E., Mirhadi, M., Kesharwani, P., & Sahebkar, A. (2024) · PharmaNutrition · doi:10.1016/j.phanu.2024.100382 · Cited by 4
A peripheral system disease—Pulmonary hypertension
Sun, Y., Chen, C., Yan, Q., Wang, S., Tan, Y., Long, J., Lin, Y., Ning, S., Wang, J., Zhang, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116787 · Cited by 4
Sun, L., Zhao, X., Guo, Y., Hou, X., Li, J., Ren, X., Dong, L., Liang, R., Nie, J., Shi, Y., et al. (2024) · International Journal of COPD · doi:10.2147/copd.s448496 · Cited by 4
Serum proteome profiling reveals HGFA as a candidate biomarker for pulmonary arterial hypertension
Zhang, M., Li, H., Ma, S., Li, X., Xi, L., Li, Y., Zhang, Z., Zhang, S., Gao, Q., Huang, Q., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-03036-1 · Cited by 4
Xu, Z., Ding, J., Liang, R., & Xie, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1502916 · Cited by 4
Reimann, L., Preiss, H., Müller, J., Huber, P., Mayer, L. C., Langleben, D., Ulrich, S., & Lichtblau, M. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003023 · Cited by 4
Scott, J. V., Tembulkar, T. U., Lee, M., Faliks, B. T., Koch, K. L., Noordegraaf, A. V., & Cook, K. E. (2022) · Physiological Reports · doi:10.14814/phy2.15136 · Cited by 4
Stubbs, H., Brewis, M. J., Church, C., & Johnson, M. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12144 · Cited by 4
The Value of Right Heart Catheterization
Ruge, M., Fischman, D. L., Rajapreyar, I. N., & Brailovsky, Y. (2023) · JACC Case Reports · doi:10.1016/j.jaccas.2023.101959 · Cited by 4
Qin, J., Wang, G., & Han, D. H. (2023) · Global Heart · doi:10.5334/gh.1274 · Cited by 4
Anderson, J., Lavender, M. A., Lau, E., Celermajer, D. S., Collins, N. J., Dwyer, N., Feenstra, J., Horrigan, M., Keating, D., KEOGH, A. M., et al. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.01.017 · Cited by 4
Imai, R., Adachi, S., Yoshida, M., Shimokata, S., Nakano, Y., Okumura, N., Murohara, T., & Kondo, T. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0640 · Cited by 4
Naing, P., Playford, D. A., Strange, G. A., Abeyaratne, A., Berhane, T., Joseph, S., Costelloe, E., Hall, M., Scalia, G. M., Forrester, D. L., et al. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.08.008 · Cited by 4
Prediction Models and Scores in Pulmonary Hypertension: A Review
Mouratoglou, S., Bayoumy, A. A., & Noordegraaf, A. V. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612824999201105163437 · Cited by 4
Sumimoto, K., Taniguchi, Y., Emoto, N., & Hirata, K. (2020) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa454 · Cited by 4
Hansmann, G., Christou, H. A., Köestenberger, M., & Sallmon, H. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13571 · Cited by 4
Chen, D., Hu, W., Xie, L., Xiang, G., Wu, Q., Qu, J., Li, S., Guan, L., & Liu, D. (2021) · Pulmonary Circulation · doi:10.1177/20458940211031111 · Cited by 4
[Pulmonary hypertension. Defining the structure and the departmental function based on risk].
Santos-Martínez, L. E. (2021) · PubMed Central · Cited by 4
Mularek‐Kubzdela, T., Wojnarski, J., Kamiński, K. A., Ochman, M., Kasprzak, J. D., Stącel, T., Kurzyna, M., Karolak, W., Mroczek, E., Kopeć, G., et al. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0259 · Cited by 4
Tamura, Y., Kumamaru, H., Nishimura, S., Nakajima, Y., Matsubara, H., Taniguchi, Y., Tsujino, I., Shigeta, A., Kinugawa, K., Kimura, K., et al. (2023) · International Heart Journal · doi:10.1536/ihj.23-047 · Cited by 4
Self-citationTamura, Y., Kumamaru, H., Tsujino, I., Suda, R., Abe, K., Inami, T., Horimoto, K., Adachi, S., Yasuda, S., Sera, F., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17050555 · Cited by 4
Self-citationPostigo, A., Mombiela, T., Bermejo, J., & Fernández‐Avilés, F. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.09.010 · Cited by 4
Mickael, C. S., Lee, M. H., & Graham, B. B. (2022) · European Respiratory Journal · doi:10.1183/13993003.00796-2022 · Cited by 4
Yasuhara, J., Watanabe, K., Watanabe, A., Shirasu, T., Matsuzaki, Y., Watanabe, H., Takagi, H., Sumitomo, N., & Kuno, T. (2023) · Cardiology in the Young · doi:10.1017/s1047951123000124 · Cited by 3
Goncharova, N. S., Борисович, Л. К., Berezina, A. V., Simakova, M. A., Маричев, А. О., Zlobina, I. S., Вачаганович, М. Н., Malikov, K. N., Aseeva, A. S., Zaĭtsev, V. V., et al. (2024) · Life · doi:10.3390/life14020259 · Cited by 3
Role of Artificial Intelligence in Assisting Pulmonary and Critical Care Clinical Decision-Making
Friedman, S. H., Long, K. J., Sexauer, S., Menon, A. A., & Kilb, E. F. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0331rr · Cited by 3
Adão, R., Barreira, B., Paternoster, E., Morales‐Cano, D., Olivencia, M. A., Quintana-Villamandos, B., Rodriguez, D. A., Cogolludo, A. L., & Pérez‐Vizcaíno, F. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00319.2024 · Cited by 3
Orozco‐Levi, M., Villegas, A. L., Camacho, R. E. C., Pacheco, M., Cortes-Colorado, J., Franco, C. J. V., Gómez-Paláu, R., de Arco, L. T. F., Luque, J. D., Pérez-Zauner, A. M., et al. (2025) · Critical Care Science · doi:10.62675/2965-2774.20250182 · Cited by 3
Advances in biomimetic nano delivery systems for pulmonary hypertension therapy
Zhao, P., Wang, M., Liu, Z., Zhang, M., Cai, Z., Zhang, B., Shi, Z., Liu, M., & Cheng, Y. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.034 · Cited by 3
Waxman, A. B., Babu, A. S., Badagliacca, R., Ferreira, E. V. M., George, P., Guazzi, M., Howard, L., Kim, D., Kovacs, G., Kubba, S., et al. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70240 · Cited by 3
Congenital Portosystemic Shunts – A Review
Wu, G. S. (2026) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00090 · Cited by 3
Gillmeyer, K. R., Johnson, S. W., Bolton, R. E., McCullough, M. B., & Wiener, R. S. (2022) · Health Services Research · doi:10.1111/1475-6773.14114 · Cited by 3
Sarkar, T., Moinuddin, S. M., Isbatan, A., Chen, J., Mann, D., & Ahsan, F. (2023) · Pharmaceuticals · doi:10.3390/ph16121656 · Cited by 3
Beyond Tumors: The Pivotal Role of TRIM Proteins in Chronic Non-Tumor Lung Diseases
Huang, X., Yu, W., Wei, A., Wang, X., & Chen, S. R. W. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s499029 · Cited by 3
Corrêa, R. D. A., Rezende, C. F., Mancuzo, E. V., Mickael, C. S., Loureiro, C. M. C., Oliveira, R. K. F., Hilton, J. F., & Graham, B. B. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70086 · Cited by 3
George, M. P., Germack, H. D., Goyal, A., Ward, C., Studer, S. M., & Panjabi, S. S. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12283 · Cited by 3
Pharmacotherapy of refractory pulmonary arterial hypertension
Ahmed, M. S., Ghallab, M., Ostrow, T. H., Nashawi, M., Alagha, Z., Levine, A., Aronow, W. S., & Lanier, G. M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2257134 · Cited by 3
Kholdani, C. A., Lee, J., Swenson, K. E., Liu, J., Hsi, A., Kudelko, K. T., Sweatt, A. J., Spiekerkoetter, E. F., Pérez, V. D. J., Rigdon, J., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70063 · Cited by 3
Cardiovascular Risk in Systemic Sclerosis
Angeloudi, E., Pagkopoulou, E., Arvanitaki, A., Σουλαϊδόπουλος, Σ., Garyfallos, A., Kitas, G. D., & Dimitroulas, T. (2020) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-020-00152-z · Cited by 3
Brunner, N. W., Legkaia, L., Alahmadi, F. B., Lee, L., Norena, M., Lam, C., Yim, J., Luong, C. L., Weatherald, J. C., Nádor, R. G., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.03.035 · Cited by 3
Hu, S., Tan, J., Liu, S., Guo, T., Song, W., Peng, F.-H., Wu, Y., Gao, X., & Hua, L. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.09.045 · Cited by 3
Zhang, Z., Liu, C., Bai, Y., Li, X., Gao, X., Li, C., Ge, G., Chen, S., Sun, M., Liu, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920222 · Cited by 3
Oxidative stress in patients with pulmonary hypertension
Wichman, T. O., Palacios, G. M. S., Davidson, R., Wichman, C., & Zimmerman, M. C. (2022) · Advances in Redox Research · doi:10.1016/j.arres.2022.100053 · Cited by 3
Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review
Lyapina, I. N., Zvereva, T. N., & Martynyuk, T. V. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.10.201875 · Cited by 3
Pulmonary hypertension in patients with multiple myeloma: A comprehensive review
Maddipati, V., Sankhyan, P., Goswami, D. P., & Mahajan, A. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12210 · Cited by 3
Papademetriou, E., Liu, X., Beaudet, A., Tsang, Y., Potluri, R. C., & Panjabi, S. S. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2204769 · Cited by 3
Yaylalı, Y. T., Yağmur, B., Sinan, Ü. Y., Meriç, M., Başarıcı, İ., Avcı, B. K., Şenol, H., Nalbantgil, S., Küçükoğlu, S., & Öngen, Z. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.2885 · Cited by 3
Valencia, L., López, S., Olivas, A. M., Becerra, Á. I. L., Alemán-Segura, M. D., Évora-García, M., Ojeda, N., Cabrera, L., Rodríguez, A., & Pérez-Peñate, G. M. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1348311 · Cited by 3
Dai, J., Liu, T., Zhang, H., Sun, X., Tang, Y., Qian, W., Zhang, Y., Ye, H., Shan, L., Li, L., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae084 · Cited by 3
Approach to a patient with pulmonary hypertension.
Inampudi, C., Hemnes, A. R., & Briasoulis, Α. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.06.007 · Cited by 3
Hansmann, G., Apitz, C., Humpl, T., Köestenberger, M., Michel‐Behnke, I., Schulze‐Neick, I., Quandt, D., & Lammers, A. E. (2020) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-020-00924-w · Cited by 3
Palliative Care and Pulmonary Arterial Hypertension
Rhee, L. S., Morgan, A. A., & DuBrock, H. M. (2022) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-21.1.7 · Cited by 3
Korman, B. D., Lachant, D. J., & Castelino, F. V. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.01.015 · Cited by 3
Insights into the management of pulmonary arterial hypertension patients in Spain
García‐Ortega, A., Lázaro, M., Utande, R., & Cuenca, V. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.04.001 · Cited by 3
Shmalts, A. A., & Gorbachevsky, S. V. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.12.000468 · Cited by 3
Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
Weatherald, J. C., Boucly, A., Savale, L., Jaïs, X., Montani, D., Humbert, M. J. C., & Sitbon, O. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3664le · Cited by 3
Pulmonary arterial compliance in patients of CHD with increased pulmonary blood flow
Choubey, M., Kothari, S. S., Gupta, S. K., Ramakrishnan, S., & Saxena, A. (2022) · Cardiology in the Young · doi:10.1017/s1047951122003341 · Cited by 2
Lung Transplantation: Selection of Candidates
Thomas, C., Williams, M., & Shlobin, O. A. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2304197 · Cited by 2
Dawes, T. J. W., Woodham, V., Sharkey, E., McEwan, A. I., Derrick, G. P., Muthurangu, V., Moledina, S., & Hepburn, L. (2024) · Pediatric Cardiology · doi:10.1007/s00246-024-03447-3 · Cited by 2
Masuda, T., Akita, K., Sato, R., Ikoma, T., Mizuno, Y., Satoh, T., Takao, M., Suwa, K., Shimizu, M., Odagiri, K., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12060216 · Cited by 2
Alsumali, A., McLaughlin, V., Chevure, J., Klok, R. M., Zhang, W., Martinez, E. C., Pausch, C., Pena, J. D. O., van de Wetering, G., Jootun, M., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03241-4 · Cited by 2
Self-citationAssociation of Pulmonary Artery Compliance and Adverse Cardiac Events
Mounsey, L. A., Nemeth, S. M., Kosyakovsky, L. B., McNeill, J. N., Picard, M. H., Pomerantsev, E. V., Parekh, J. K., Schoenberg, N. C., Furfaro, D. M., Kholdani, C. A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102357 · Cited by 2
Piłka, M., Darocha, S., Waligóra, M., Kopeć, G., Florczyk, M., Torbicki, A., Mularek‐Kubzdela, T., Smukowska-Gorynia, A., Lewicka, E., Mroczek, E., et al. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04250-4 · Cited by 2
Yang, E., Chen, M., Wu, M., Dong, Q., Li, J., Xu, H., Qu, B., Zhang, H., Jin, Z., Li, G., et al. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01522-6 · Cited by 2
Experience with Selexipag to Treat Pulmonary Arterial Hypertension
Karelkina, E. V., Goncharova, N. S., Simakova, M. A., & Моисеева, О. М. (2020) · Kardiologiia · doi:10.18087/cardio.2020.4.n1026 · Cited by 2
Camacho, R. E. C., Orozco‐Levi, M., Londoño, A., Acosta, D. F., Alvarado, J. J., Carvajal, J. F., Camargo-Mendoza, J. P., Gómez-Paláu, R., Martínez-Ramírez, I. J., Méndez, J., et al. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.22000022 · Cited by 2
Cardiologia Teoria e Prática - Edição XI
Freitas, G. B. L. D., de Souza, A. R. C., Vieira, E. M. M. D. P. M., & de Almeida, C. C. (2023) · doi:10.59290/978-65-6029-060-0 · Cited by 2
Pulmonary Hypertension Associated with Connective Tissue Disease
Mathai, S. C. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.03.005 · Cited by 2
Paoli, C. J., Zhang, C. Z., Tang, X., Panjabi, S. S., Thompson, A., & El‐Kersh, K. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108112 · Cited by 2
ATS Core Curriculum 2020. Adult Pulmonary Medicine
Channick, C. L., Garrison, G. W., Huie, T. J., Narewski, E., Caplan‐Shaw, C., Cho, J., Rafeq, S., Alalawi, R. H., Alashram, R., Bailey, K. L., et al. (2020) · ATS Scholar · doi:10.34197/ats-scholar.2020-0016re · Cited by 2
Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
Sun, X., Chen, R., Yao, X., Zheng, Z., Wang, M., Wang, C., & Cheng, J. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1965le · Cited by 2
Stubbe, B., Halank, M., Seyfarth, H., Obst, A., Desole, S., Opitz, C. F., & Ewert, R. (2022) · Pneumologie · doi:10.1055/a-1740-3377 · Cited by 2
Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report
Mohan, N., Dalip, D., & Jaggernauth, S. (2022) · Cureus · doi:10.7759/cureus.29699 · Cited by 2
Role of Pulmonary Rehabilitation in Patients with Pulmonary Arterial Hypertension
Al-Tantawy, M., Al-Sayd, M., Al-Sayd, Y. A., & Al-Aty, M. A. (2022) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.21608/aimj.2022.130625.1894 · Cited by 2
Chen, S., Wei, X., Zhang, X., Yao, M., Qiu, Z., Chen, L., & Zhang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1028058 · Cited by 2
Incorporation of noninvasive assessments in risk prediction for pulmonary arterial hypertension
Quan, R., Chen, X., Yang, T., Li, W., Qian, Y., Lin, Y., Xiong, C., Shan, G., Gu, Q., & He, J. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12158 · Cited by 2
Metadata
- Authors
- Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., & McLaughlin, V. V.
- Affiliations
- University of Bologna (IT)
- Harvard University (US)
- Mayo Clinic (US)
- University Hospital Heidelberg (DE)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tufts University (US)
- Houston Methodist (US)
- International University of Health and Welfare (JP)
- University of Michigan (US)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801889
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351343
- OpenAlex
- W2904385559
- Cited by
- 819
- References
- 88
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 101 · 2023: 108 · 2022: 174 · 2021: 169 · 2020: 128 · 2019: 58
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Funders
- Japan Society for the Promotion of Science (18K08183)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, risk stratification, medical therapy, combination therapy, treatment escalation, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues, right ventricular function, exercise capacity, one-year mortality, lung transplantation, treatment algorithm
- MeSH terms
- Pulmonary Arterial Hypertension, Calcium Channel Blockers, Humans, Randomized Controlled Trials as Topic, Lung Transplantation, Practice Guidelines as Topic, Risk Assessment, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.